U.S. markets closed

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
441.88+1.67 (+0.38%)
At close: 4:00PM EDT
441.88 0.00 (0.00%)
After hours: 04:39PM EDT

Bio-Techne Corporation

614 McKinley Place NE
Minneapolis, MN 55413
United States
612 379 8854

Full Time Employees2,300

Key Executives

NameTitlePayExercisedYear Born
Mr. Charles R. KummethCEO, Pres & Director2.86M20.79M1960
Mr. James T. HippelExec. VP of Fin. & CFO1.15M4.24M1971
Ms. Brenda S. FurlowSr. VP, Gen. Counsel, Sec. & Chief Compliance Officer821.24k1.88M1958
Mr. Norman David EansorPres of Protein Sciences Segment1.08M5.71M1961
Mr. Kim KeldermanPres of Diagnostics & Genomics972.4kN/A1967
David ClairSr. Director of Investor Relations & Corp. Devel.N/AN/AN/A
Mr. Gerry AndrosVP of Sales and MarketingN/AN/AN/A
Mr. Struan RobertsonVP of HRN/AN/AN/A
Mr. Robert M. GavinSr. VP of Analytical Solutions DivisionN/AN/A1968
Mr. Kevin S. GouldSr. VP of Diagnostics Reagents DivisionN/AN/A1966
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporation’s ISS Governance QualityScore as of June 1, 2021 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.